ANI Pharmaceuticals, Inc. has established The FutureVision Advisory Council to advance its ophthalmology and retina franchise in Rare Disease. The distinguished council includes seven retina specialists and three uveitis specialists. The Council is led by Dr. Khanani and Dr. Chang, who aim to guide ANI’s future innovations. The portfolio includes ILUVIEN for diabetic macular edema and Purified Cortrophin Gel for severe allergic and inflammatory conditions affecting different parts of the eye. Safety information and adverse reactions are provided for each product. ANI is committed to serving patients and improving lives through innovative therapeutics.

Read more at GlobeNewswire: ANI Pharmaceuticals Announces Formation of “FutureVision